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Abstract According to an epi-
demiological study in Japan, there
are as many as 22 million patients
with tension headache and 8.4 mil-
lion with migraine. Furthermore,
patients suffering from both types
of headache concurrently are esti-
mated to account for more than
50% of headache patients. We
studied the efficacy of drug thera-
py for migraine accompanied by
tension headache-like symptoms,
focusing principally on neck stiff-
ness. We evaluated the efficacy of
rizatriptan by comparison of find-
ings before and after therapy in 34
migraine patients, consisting of 16
without neck stiffness (migraine
without neck factor: WONF) and
18 with it (migraine with neck fac-
tor: WNF), who received treat-
ment at our neurology/internal
medicine department from 1
March 2004 to 31 May 2005. In
the study, all the patients were
asked to keep a record of their
migraine status. The severity of
migraine was classified by physi-
cians according to the
International Headache Society
diagnostic criteria, based on which
drug efficacy was evaluated. We
selected rizatriptan for migraine
treatment in our study based on
Dr. Ferrari’s report. In the efficacy
study of rizatriptan, in the group
of 34 migraine patients, the pain
relief rate (79.4%) and pain-free
rate (41.2%) at two hours after
treatment were as high as those
reported in the meta-analysis per-
formed by Ferrari et al., indicating
high efficacy of rizatriptan. In the
efficacy comparison between the
WONF and WNF groups, the pain-
free rates were 56.3% and 27.8%,
and cumulative pain relief rates
were 100% and 61.1%, respective-
ly, with better results in the
WONF group. A test result was
also significantly better
(p=0.0076) in the WONF group.
Rizatriptan was proved effective
in treating migraine patients
accompanied by tension headache-
like symptoms. Comparison of
efficacy rates between patient
groups with and without tension
headache-like symptoms showed
that the pain relief rate in the
group without neck stiffness was
higher.
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Introduction
While their causes are diverse, headaches that are recur-
rent and have no organic disease as their cause are classi-
fied as primary headaches (chronic headache), and are
represented by migraine, tension headache and cluster
headache. Among these three, tension headaches are the
most frequently reported epidemiologically.
There are reports, however, that many patients visiting
medical facilities for treatment of self-reported symptoms
characteristic of tension headache and other chronic
headaches were actually suffering from migraine, result-
ing in inappropriate diagnosis and treatment [1–4].
While neck stiffness is widely regarded as a symp-
tom accompanying tension headache, it is also frequent-
ly observed in migraine patients, a finding not well
understood by either physicians or patients themselves.
This often leads to diagnosis and treatment of migraine
as tension headache. Another reason for frequent incor-
rect diagnosis of migraine as tension headache is relat-
ed to shifts in the site at which pain occurs during a
migraine attack: for example, pain on one side of the
head sometimes spreads to both sides, and non-pulsatile
pain at the beginning of an attack often shifts to pul-
satile pain at the most advanced stage of the headache.
For these reasons, if a patient complains of bilateral and
non-pulsatile pain, the condition may be diagnosed as
tension headache even though there are other factors
indicating migraine.
According to an epidemiological study in Japan, there
are 22 million patients with tension headache and 8.4 mil-
lion with migraine, both of which are thus high in inci-
dence. Furthermore, patients suffering from both concur-
rently are estimated to account for more than 50% of
headache patients. We therefore studied the efficacy of
drug therapy for migraine, focusing on the symptom of
neck stiffness.
Methods
We evaluated the efficacy of rizatriptan by comparison of find-
ings before and after therapy in 34 migraine patients, consisting
of 16 without neck stiffness (migraine without neck factor:
WONF) and a mean age of 33.5±8.8 years and 18 with it
(migraine with neck factor: WNF) and a mean age of 37.1±11.2
years, who received treatment at our neurology/internal medi-
cine department from 1 March 2004 to 31 May 2005.
All the patients were asked to keep a record of their migraine
status at designated times. The severity of migraine was classi-
fied by physicians according to the International Headache
Society diagnostic criteria, based on which efficacy was evalu-
ated by comparison of findings before and after therapy.
Study design
We selected rizatriptan for migraine treatment in our study
based on a report by Ferrari et al. published in The Lancet in
2001 [5].
Patients were asked to fill in the chronic headache check
sheet, which had been provided in advance, so as to obtain a bet-
ter understanding of their types of headaches. In addition, they
were asked to keep a record of their migraine status to gather
data on the severity and frequency of headaches, based on which
physicians evaluated severity and efficacy of treatment. The
severity of headaches and impact on daily life were recorded
using a three-level scale (3 for severe, 2 for moderate and 1 for
mild) before receiving rizatriptan and a four-level scale (3 for
severe, 2 for moderate, 1 for mild and 0 for none) two hours after
receiving rizatriptan and whenever an attack occurred in the
morning, afternoon or at night.
Statistical analysis
Distributions of baseline characteristics of patients before thera-
py in the two groups were analysed by Fisher’s exact probabili-
ty test, and statistical data such as age and disease period by the
unpaired t-test. Differences in efficacy judgements between the
two groups were analysed using the Mann-Whitney U-test. The
significance level for all tests was 5%.
Results
Table 1 shows the characteristics of the subject groups and
headache severity before therapy. There were more
females among the evaluable subjects. The mean disease
periods in the WONF and WNF groups were 34.4 and
33.5 months, and the mean numbers of attacks 6.4 and 6.5,
respectively, with no significant differences between the
two groups. The mean attack durations in the WONF and
WNF groups were 3.8±2.39 (mean±SD) and 6.5±4.07
(mean±SD) (p=0.0858). There were no differences in dis-
tributions of age, severity of headache or presence/absen-
ce of pressure pain between the two groups. The adminis-
tration times varied from patient to patient: some took the
medication at a signalling stage and others immediately
after a headache attack or at the most advanced stage. The
mean time of administration after start of a headache was
5.5±2.0 h.
Table 2 shows the result of efficacy comparison for
rizatriptan. For the group of all 34 migraine patients, the
pain relief and pain-free rates at two hours after treatment
were 79.4% and 41.2%, respectively, demonstrating effi-
cacy as high as that reported in the meta-analysis con-
ducted by Ferrari et al. [5]. In a comparison between the
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WONF and WNF groups, the pain-free rates were 56.3%
and 27.8% and cumulative pain relief rates were 100%
and 61.1%, respectively, with better results in the WONF
group. The Mann-Whitney test result confirmed the sig-
nificant superiority (p=0.0076) of the WONF group.
Discussion
Migraine interferes with daily life, not only decreasing
patients’ quality of life but that of their families.
According to a report, of patients with chronic headache
who complained of adverse impacts on their daily lives,
90% were suffering from migraine and 10% from tension
headache [6], indicating a significant difference in impact
on daily life and activities between the two types of
headache. Medication, if it is properly administered,
would be one option to mitigate the impact of migraine on
daily life and activities.
Rizatriptan [7–9], the investigational drug in our study,
is a second-generation 5-HT 1B/1D receptor agonist, in
association with which very few adverse drug reactions
have been reported. Sheftell et al. [10] reported that
patients receiving rizatriptan experience switching to
other drugs least frequently. Ninan et al. [11] reported that
the pain-free rate in migraine patients receiving rizatriptan
at an early stage was significantly higher than those for
patients receiving other triptans.
Both physicians and patients are poorly aware of the
fact that neck stiffness is frequently observed among
migraine patients. Physicians often diagnose patients as
suffering from tension headache simply because patients
complain of headache associated with a stiff neck. We
therefore evaluated the efficacy of rizatriptan, mainly
focusing on neck stiffness, in 16 patients without neck
stiffness (WONF) and 18 with it (WNF).
Blau et al. [12] reported that neck stiffness could
induce migraine. Kaniecki and Totten [13] reported that
75% of migraine patients concurrently suffer from neck
pain, which occurs at any of the stages: signalling,
headache or mitigating. They also reported that it is dif-
ficult in the clinical setting to correctly diagnose
whether the condition is migraine or tension headache,
and that therefore physicians should select a medication
that can treat the symptoms of both [14]. In their report,
they added that sumatriptan therapy in migraine patients
accompanied by neck stiffness and other tension-type
symptoms successfully improved both headache and ten-
sion-type symptoms. In our study, rizatriptan therapy
exhibited efficacy in pain relief in the WNF regardless
of when neck stiffness occurred, along with or before or
after an attack. Despite confirmation of efficacy, the
pain relief and pain-free rates in the WNF group were
lower than those in the WONF group. Furthermore, the
level of satisfaction with efficacy of therapy was lower
in the WNF group, even for those where headache dis-
appeared or was improved, than for those in the WONF
group, and re-onset of neck stiffness with regard to riza-
triptan was 36.4%.
The neck stiffness in the WNF group was different in
nature from that associated with tension headache. In
patients with chronic stiff neck, the symptom tends to
become stronger when a headache occurs. Neck stiffness
that occurred at the onset of headache was very likely to be
classified as radiating pain in the cervical area through the
Table 1 Baseline characteristics
Item Category Migraine without Migraine with neck p-value
neck factor group factor group
Age, years 33.5±8.75 (n=16) 37.1±11.16 (n=18) 0.3060
Sex Male:female 4:12 4:14 0.5826
Disease period, months 34.4±43.44 (n=8) 33.5±28.35 (n=10) 0.9595
Severity of headache Moderate:severe 13:3 14:4 0.5708
Frequency of headache, hours 6.4±3.01 (n=16) 6.5±2.98 (n=18) 0.9519
Mean attack duration, hours 3.8±2.39 (n=12) 6.5±4.07 (n=10) 0.0858
Presence/absence of pressure pain Presence:absence 5:11 6:11 0.5493
Table 2 Result of efficacy comparison
Disappeared, n (%) Improved, n (%) No change Mann-Whitney
Migraine without neck factor group 9   (56.3) 7   .(100) 0 p=0.0076
Migraine with neck factor group 5   (27.8) 6   (61.1) 7
Total 14   (41.2) 13   (79.4) 7
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spinal trigeminal nucleus. If more than one type of neck
stiffness is observed in migraine patients, responses to riza-
triptan therapy could also vary. This can explain the signifi-
cant differences in pain relief and pain-free rates between
the WONF and WNF groups. All things considered, in treat-
ing migraine patients with neck stiffness, use of eperisone
hydrochloride or other drugs in addition to rizatriptan might
be effective. For migraine patients with chronic neck stiff-
ness, preventive measures should also be considered.
Rizatriptan therapy was found in this study to be effec-
tive in both migraine patient groups with and without neck
stiffness. When patients with chronic headache chiefly
complain of headaches severe enough to interfere with
their daily lives, physicians should suspect migraine,
regardless of the occurrence of neck stiffness, in diagno-
sis and provision of appropriate treatment.
Conclusions
Our study demonstrated the efficacy of rizatriptan in
improving headache symptoms in migraine patients with
neck stiffness. We recommend use of drug therapy in
accurately diagnosed migraine patients with neck stiff-
ness. We have suggested that although neck stiffness does
not make triptans ineffective, coadministration might
improve outcome.
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